trending Market Intelligence /marketintelligence/en/news-insights/trending/tvm3ynqq-16jduulauwjka2 content esgSubNav
In This List

NYSE accepts CorMedix's plan to regain compliance with listing requirements

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


NYSE accepts CorMedix's plan to regain compliance with listing requirements

CorMedix Inc. said the New York Stock Exchange accepted its plan to regain compliance with its listing requirements.

The Brisbane, Calif.-based company had said in June that it received a noncompliance notice from the NYSE American.

The biopharmaceutical company had reported a stockholders' equity of $800,000, lower than a minimum of $2 million as required by NYSE.

CorMedix, which submitted its plan on July 16, has until Dec. 16, 2019 to regain compliance.